14.53
+0.07%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wuhan Easy Diagnosis Biomedicine Co
Its shares trade on Shenzhen under the ticker 002932.SZ. It has been listed since 10 July 2018. In the fiscal year to 31 December 2025, it reported a net loss of CN¥16.5m. At that date it held total assets of CN¥5.98bn and shareholders' equity of CN¥5.53bn.
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is engaged in the manufacturing and selling of the Diagnosis Biomedicine related equipment. The company is headquartered in Wuhan, Hubei. The company went IPO on 2018-07-10. The firm's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The firm's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 10 Jul 2018
- Employees
- 1,547
- Website
- mdeasydiagnosis.com ↗
Leadership
Pay as last reported
- Ms. Lili ChenChairman of the Board, General Manager, since 2013CN¥502,500
- Ms. Ying WangVice Chairman of the Board, Deputy General Manager, since 2008CN¥486,400
- Mr. Rui WangFinance Director, Deputy General Manager, Secretary of the BoardCN¥1.0m
- Mr. Jianfei WangDirector
- Mr. Zhenlu ZhangDirectorCN¥120,000
- Mr. Peng DengIndependent DirectorCN¥50,000
- Ms. Yi QuanIndependent DirectorCN¥50,000
- Mr. Xianwang ShiIndependent DirectorCN¥9,500
- Mr. Jincheng XieIndependent DirectorCN¥50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wuhan Easy Diagnosis Biomedicine Co Ltd employs 1547 employees in Wuhan, China.
- The company manufactures POCT rapid diagnostic reagents for six disease categories including infectious diseases.
- Its main products are used in domestic hospitals, health service centers, and community clinics across China.
Weaknesses
- The company's IPO was on 10 July 2018, which may indicate limited market experience.
- Wuhan, Hubei, is a city with high competition in the Health Care sector.
- The firm's products are primarily used in domestic medical institutions, limiting international expansion.
Opportunities
- The growing demand for POCT diagnostic reagents in China's health care sector presents significant opportunities.
- Expanding into international markets could leverage the company's expertise in rapid diagnostic reagents.
- Increasing healthcare infrastructure in China supports the demand for diagnostic equipment.
Threats
- The Health Care sector in China faces regulatory changes that could impact product approvals.
- Competition from established domestic and international firms in the diagnostic reagents market is intense.
- Economic downturns in China could reduce healthcare spending and affect sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.